Selank

What is Selank?#

Selank is a peptide that has been studied in preclinical and clinical research models for its potential therapeutic properties.

Mechanism of Action#

Selank is a synthetic heptapeptide derived from the endogenous immunomodulator tuftsin (Thr–Lys–Pro–Arg–Pro–Gly–Pro). Current evidence supports a multimodal mechanism encompassing GABAergic allosteric modulation, indirect engagement of the opioid system via enkephalinase inhibition, neurotrophin-linked plasticity, and coordinated neuroimmune transcriptomic regulation, rather than a single high-affinity receptor target.

Primary receptor interactions and molecular targets

• GABAergic system: In vivo and cellular studies indicate that Selank modulates the GABAA receptor system in an allosteric manner. Intranasal Selank alters the number of [3H]GABA-specific binding sites in cortical tissue without changing affinity, and gene-expression changes after Selank show a positive correlation with those induced by exogenous GABA. Functionally, Selank augments diazepam’s anxiolytic effect in stressed rats, consistent with facilitation of benzodiazepine-sensitive GABAA signaling.
• Enkephalinase inhibition and opioid pathway: Biochemical data show that Selank inhibits serum enkephalin-degrading enzymes (including aminopeptidases, enkephalinase B/NEP 24-11, and ACE/enkephalinase A), increasing endogenous enkephalin levels and thereby indirectly engaging opioid receptors. Behavioral pharmacology (naloxone sensitivity) supports involvement of the opioid system in Selank’s effects.
• Neurotrophic factors: Selank upregulates Bdnf mRNA and increases BDNF protein in hippocampus following intranasal administration. The mechanistic implication is potentiation of BDNF–TrkB signaling with downstream PI3K–AKT, MAPK/ERK, and PLCγ cascades that support synaptic plasticity and neuroprotection (inference from BDNF biology).
• Transporters and ion homeostasis: Transcriptomic profiling identifies Selank-driven regulation of ion/neurotransmitter transporters, including upregulation of SLC8A3/NCX3 and modulation of SLC1A2 (EAAT2), SLC5A7 (choline transporter), and SLC6A20. These changes implicate altered Na+/Ca2+ handling and glutamatergic/cholinergic transmission, with downstream effects on excitability and plasticity.
• Neuroimmune targets: Selank modulates the fractalkine receptor CX3CR1 and broad panels of cytokine/chemokine genes in spleen and brain, linking it to neuron–microglia communication and antiapoptotic NF-κB and AKT signaling axes.

Signaling pathways

• GABAergic potentiation: Allosteric enhancement of GABAA receptor function increases inhibitory tone, which can secondarily reshape activity-dependent transcription programs. Correlated gene-expression signatures with GABA and increased [3H]GABA binding site number support this pathway.
• Opioid signaling via preserved enkephalins: By inhibiting enkephalinases, Selank elevates endogenous enkephalin tone, activating Gi/o-coupled opioid receptors and impacting cAMP, ERK/MAPK, and AKT pathways that contribute to anxiolysis and stress resilience (inference consistent with observed pharmacology).
• BDNF–TrkB cascades: Increased hippocampal BDNF suggests engagement of canonical TrkB pathways—PI3K–AKT, MAPK/ERK, PLCγ—promoting survival and synaptic plasticity, consistent with behavioral and neuroprotective profiles.
• Ion/Ca2+ signaling and plasticity: Upregulated NCX3 (SLC8A3) predicts changes in intracellular Ca2+ dynamics that can influence AKT/CREB-dependent plasticity programs.
• Neuroimmune NF-κB/AKT signaling: Changes in CX3CR1 and immune gene sets imply modulation of NF-κB and AKT within microglia-neuron crosstalk, aligning with reported antiapoptotic and immunocorrective effects.

Context of tuftsin/neuropilin-1 Selank is a tuftsin family analogue. Tuftsin binds neuropilin‑1 and can signal via VEGF/TGF-β–related axes; however, there is no direct biochemical evidence that Selank itself binds neuropilin‑1. Any neuropilin‑linked mechanisms for Selank remain speculative without direct binding data.

Integrated mechanism Collectively, Selank acts as a pleiotropic neuromodulator: it enhances inhibitory GABAergic transmission, preserves endogenous enkephalins to modulate opioid pathways, increases neurotrophic support (BDNF), and reprograms neural and immune transcriptomes, including ion transport and microglia–neuron communication genes. These convergent actions likely underlie its anxiolytic, antistress, and neuroprotective profiles.

Key uncertainties

• Direct, high-affinity receptor binding of Selank to GABAA or neuropilin‑1 has not been structurally demonstrated. Most GABAergic evidence is functional/transcriptomic. Opioid involvement appears indirect via enkephalinase inhibition. Thus, Selank should be considered a multimodal peptide with indirect and network-level mechanisms rather than a single-target ligand.

Therapeutic Applications#

Therapeutic applications and documented outcomes

Anxiety disorders (generalized anxiety disorder, adjustment disorder)

• Generalized anxiety disorder (GAD): In a clinical study of 20 adults receiving intranasal Selank 2700 μg/day, two response patterns were observed. Rapid responders (≈40%) showed HARS reduction from 20.3 [11.9] to 7.0 [2.9] by Day 3 (p<0.01); conventional responders improved from 16.1 [7.2] to 6.2 [4.7] by Day 14 (p<0.01). A single 900 μg dose produced pharmaco‑EEG changes (↑beta, ↓theta/low‑alpha; p<0.05). A review summarizing clinical comparisons reported Selank’s anxiolytic efficacy comparable to medazepam in GAD/neurasthenia, and distinct biomarker effects (increased serum Leu‑enkephalin; inhibition of enkephalin‑degrading enzymes), which were not seen with medazepam.
• Adjustment disorder: In a small randomized study (n=30), patients receiving Selank for two weeks improved more than untreated controls on PHQ domains: somatic symptoms (mean 1.2 vs 3.6), nutritional problems (0.1 vs 3.4), and alcohol misuse (0.3 vs 1.5) at 2 weeks (all p<0.05).

Mechanistic and biomarker findings supporting anxiolysis

• Clinical and preclinical observations indicate modulation of the enkephalinergic system: decreased baseline enkephalin half‑life and increased enkephalinase activity in anxious patients were counteracted by Selank, which increased serum Leu‑enkephalin and inhibited enkephalin‑degrading enzymes in vitro (~15 μM range). Intranasal Selank and an Arg–Pro–Gly–Pro fragment altered [3H]GABA binding site numbers without changing affinity, aligning with a GABAA‑related mechanism.

Stress resilience and interaction with benzodiazepines (preclinical)

• In rats exposed to unpredictable chronic mild stress (UCMS), Selank (300 μg/kg intranasal, 14 days) reduced anxiety‑like behavior, and the Selank+diazepam combination was most effective: compared with UCMS+saline, open‑arm time increased 8.9‑fold and closed‑arm time decreased 2‑fold; UCMS itself reduced open‑arm time 13.6‑fold and hanging events 5.7‑fold (elevated plus maze). Earlier work in stress/novelty paradigms reported Selank (≈300 μg/kg) increased peripheral activity (+63.4%), vertical activity (+10.2%), and exploratory hole‑poking (+23.0%), and improved escape behavior—consistent with anti‑anxiety and pro‑adaptive effects.

Neuroimmune and peripheral actions

• Social stress model (rodents): Selank restored delayed‑type hypersensitivity (DTH), direct agglutination (DAT) responses, neutrophil phagocytic activity, and normalized leukocyte differentials versus stressed controls, supporting immunocorrective action under stress.
• Tissue repair model: In rats with thermal burns, systemic Selank (100 μg/kg daily, i.p.) accelerated reparative regeneration, with earlier granulation/epithelization, earlier scab rejection, and partial wound closure, compared with untreated animals (histological endpoints).
• Hemostasis: Comparative work on proline‑containing oligopeptides suggested Selank has distinct effects on anticoagulant/primary hemostasis parameters, indicating potential peripheral actions that may be relevant to safety and therapeutic development.

Scope and limitations

• Clinical data are limited to small studies and abstracts; randomized, controlled, and adequately powered trials remain scarce in the international literature. Nevertheless, consistent anxiolytic signals, rapid onset in a subset of patients, EEG correlates, and neuropeptide biomarker modulation support further clinical investigation.

Key study details are tabulated here for reference:

Preclinical Evidence#

Overview and scope Selank (TP-7; Thr-Lys-Pro-Arg-Pro-Gly-Pro) is an intranasal heptapeptide derived from the immunomodulatory tetrapeptide tuftsin. It is promoted as an anxiolytic with possible cognitive, neuroimmune, and GABAergic effects. The accessible evidence base comprises: (1) very limited human clinical data, largely from small, domestic studies and a conference abstract; (2) several preclinical rodent and molecular studies suggesting anxiolytic-like effects and multimodal mechanisms; and (3) a narrative review claiming domestic registration in Russia of a 0.15% nasal formulation. Overall, the evidence quality for efficacy in anxiety disorders is low, with substantial gaps and risk of bias.

Extent and quality of human clinical evidence • Controlled trials: No randomized, blinded, placebo-controlled trials were identified in major international registries or the accessible literature. Searches did not yield NCT-registered interventional trials of Selank. • Uncontrolled study (conference abstract): A small intranasal study in adults with DSM-IV generalized anxiety disorder (n=20) reported two response profiles: approximately 40% “rapid responders” (HARS reduction by Day 3) and 60% “conventional responders” (improvement by Day 14). Acute pharmaco-EEG after a single 900 µg dose showed increased beta and decreased theta/low alpha in rapid responders. The abstract lacks a control group, randomization, blinding, detailed safety reporting, and longer follow-up, substantially limiting inference. • Domestic clinical use reports: A narrative review describes clinical use and claims Russian registration of a 0.15% intranasal formulation, and summarizes open-label experience in anxiety/neurasthenia, including rapid and gradual symptom improvements. These accounts provide insufficient methodological detail and lack independent replication.

Preclinical and mechanistic evidence • Behavioral models: In rodents, Selank shows anxiolytic-like activity and can enhance diazepam’s effect in an unpredictable chronic mild stress model, with the combination restoring anxiety measures to pre-stress values. Sample sizes are small and durations short. • GABAergic modulation: Intranasal Selank alters expression of neurotransmission genes, with many changes overlapping GABA’s early transcriptional signature, and prior binding data suggest effects on GABAA receptor–related binding. These findings support a possible GABAergic, allosteric-modulatory component, but are limited by short time frames, pooled tissues, and gene-expression endpoints without direct functional confirmation in humans. • Other pathways: Preclinical studies report modulation of monoamines (noradrenaline, dopamine, serotonin), increased hippocampal Bdnf mRNA and BDNF protein, effects on enkephalin metabolism via inhibition of enkephalin-degrading enzymes, and neuroimmune-related gene changes (e.g., Casp1, Bcl6, C3). These point to a multimodal mechanism but remain predominantly preclinical and variably strain- and dose-dependent.

Safety and tolerability Accessible clinical sources provide minimal systematic safety data. Reviews claim anxiolytic effects “without” typical benzodiazepine adverse effects, but this is not substantiated by robust controlled human datasets. Preclinical reports do not substitute for clinical pharmacovigilance. Accordingly, the certainty about human safety and adverse events is low.

Regulatory status and registration A narrative review states the Selank 0.15% nasal formulation “was registered by the Russian Federation Ministry of Health and approved for medical use.” Independent verification within major international regulators or registries was not identified in our searches. The lack of registered international RCTs further limits external validation.

Key limitations, evidence gaps, and criticisms • Lack of robust human RCTs: No randomized, blinded, placebo-controlled trials with transparent protocols, prespecified endpoints, and adequate sample sizes are evident in major registries or the accessible literature. • Small, uncontrolled clinical signals: The only accessible human study is a small, uncontrolled conference abstract with short follow-up and limited safety reporting, precluding causal inference. • Reliance on preclinical and domestic literature: Much of the evidence comes from developer-affiliated groups and domestic sources, with limited independent, international replication and several methodological constraints. • Surrogate and mechanistic endpoints: Heavy emphasis on acute gene-expression changes, binding studies, and EEG correlates rather than durable, clinically meaningful outcomes. • Mechanism incompletely defined in humans: While GABAergic, enkephalin, monoaminergic, BDNF, and neuroimmune pathways are implicated in animals, confirmation in humans is lacking. • Safety data sparse: Absence of systematic adverse event collection and long-term safety surveillance in controlled clinical settings. • Generalizability and bias risk: Small samples, strain- and dose-dependence in animals, potential conflicts of interest, and quality concerns for some journals limit confidence and generalizability.

The current evidence base for Selank consists primarily of preclinical studies and a small, uncontrolled human report. Signals for anxiolytic-like effects and multimodal mechanisms exist in animals, including GABAergic and neuroimmune modulation and interaction with benzodiazepines. However, the clinical efficacy and safety of Selank in anxiety disorders remain unproven by modern standards due to the absence of high-quality randomized, controlled human trials, limited transparent safety data, and scarce independent replication. Rigorous, preregistered, placebo-controlled RCTs with standardized outcomes and safety monitoring are needed before strong clinical claims can be substantiated.

Evidence summary table

Evidence Gaps and Limitations#

The current evidence base for Selank consists primarily of preclinical studies. Key limitations include:

• No completed randomized controlled trials in humans
• Most data derived from animal models, limiting direct translatability
• Publication bias may favor positive results
• Long-term safety data in humans is not available
• Optimal dosing for human applications has not been established

Key Research Findings#

A New Generation of Drugs - Synthetic Peptides Based on Natural Regulatory Peptides, published in Neuroscience and Medicine (Kolomin TA et al., 2013; DOI: 10.4236/nm.2013.44032):

• The study demonstrated of GAD patients showed rapid response by day 3 of 40%

Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo, published in Doklady Biological Sciences (Inozemtseva LS et al., 2008; PMID: 18841804):

• The study showed BDNF protein levels increased by 24 hours at both doses tested

Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission, published in Frontiers in Pharmacology (Volkova A et al., 2016; PMID: 26924987):

• The study showed selank altered expression of 45 neurotransmission genes in rat frontal cortex at 1 hour, with changes overlapping GABA induced transcriptional signatures

Related Reading#

• Selank research studies and evidence
• Selank dosing protocols
• Selank side effects profile
• Cerebrolysin research guide
• Nemifitide research guide